Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pearson implementation

This article was originally published in The Tan Sheet

Executive Summary

Consumer perception research will be conducted to determine rules that would best assure truthful and nonmisleading health claims on dietary supplements, FDA tells Rep. David McIntosh (R-Ind.), chairman of the House Subcommittee on National Economic Growth, Natural Resources & Regulatory Affairs in a May 16 letter. Reps from academia, consumer research and advocacy groups called for such research at a public meeting April 4 (1"The Tan Sheet" April 10, p. 5). Responding to a March 13 letter from McIntosh on various aspects of the Pearson implementation process, FDA says the court ruling affects only dietary supplements because "FDA does not have authority to authorize health claims for conventional foods when such a claim would require a disclaimer to render it truthful and not misleading"

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel